Overview Of Medanta Global Health Limited ::
One of the biggest private, multi-specialty tertiary care providers in India’s North and East is Global Health Limited. Cardiology and cardiac science, neurosciences, cancer, digestive and hepatobiliary sciences, orthopaedics, liver transplant, renal and urology are among the company’s major specialties.
Under the “Medanta” name, Global Health Limited currently operates a network of four hospitals in Gurugram, Indore, Ranchi, and Lucknow. The Medanta Institutional Tissue Repository was developed by the firm in 2017 to advance tissue-based research on biomarkers and other topics.
The firm produced revenue from healthcare services totaling Rs. 14,805.71 million, Rs. 14,178.41 million, Rs. 21,003.95 million, Rs. 4,732.10 million, and Rs. 5,960.89 226 million, respectively, in the fiscal years 2020, 2021, and 2022 as well as the three months ended June 30, 2021 and 2022.
EBITDA of Rs. 2,304,54, Rs. 2,228,52, Rs. 4,897,57, Rs. 1,057,69, and Rs. 1,416.46 million, in that order.
By June 30, 2022, the company will have 2,467 installed beds across its operational hospitals, which cover a space of 4.7 million square feet and employ over 1,300 doctors under the direction of seasoned department heads.
The Gurugram hospital of Worldwide Health Limited was named the best private hospital in India for three years in a row in 2020, 2021, and 2022. It was also the only private hospital in India to appear on Newsweek’s lists of the top 200 global hospitals in 2021 and the top 250 global hospitals in 2022.
Strengths of Medanta Global Health Limited:
- Leading tertiary and quaternary care facility in India, highly regarded for clinical proficiency, particularly when handling challenging situations.
- Focus on academia and clinical research
- large-scale hospitals with top-notch infrastructure, cutting-edge medical technology, and equipment.
- A history of excellent operational and financial results.
- Concentrate efforts on underserved areas with high populations and make an appearance in the largest or capital cities of big states (NCR, Lucknow and Patna).
- Opportunities for expanding current facilities and expanding into new services, such as digital health.
- Significant institutional shareholder support and an experienced senior management team.
Company Financials
Global Health Limited Financial Information (Restated)
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Total Borrowing |
| 31-Mar-20 | 2666.29 | 1544.27 | 36.33 | 1349.54 | 621.94 |
| 30-Jun-20 | 2855.11 | 491.58 | 41.76 | 1425.38 | 725.07 |
| 31-Mar-21 | 2694.1 | 1478.16 | 28.8 | 1382.34 | 644.6 |
| 31-Mar-22 | 3145.52 | 2205.82 | 196.2 | 1616.01 | 837.86 |
| 30-Jun-22 | 3221.94 | 626.54 | 58.71 | 1675.55 | 794.45 |
| Amount in ₹ Crore | |||||
Objects of the Issue ::
The company proposes to utilize the net proceeds of the Fresh Issue towards funding of the following objects:
- Repayment/prepayment of borrowings, in full or part, of the Subsidiaries, GHPPL and MHPL.
- General corporate purposes.
Grey Market Premium Of Medanta Global limited(GMP) ::
Global Health shares are currently trading on the black market for a premium (GMP) of 19. On Wednesday, November 16, 2022, the company’s shares are anticipated to list on the top stock exchanges BSE and NSE.
Global Health IPO Details
| IPO Date | Nov 3, 2022 to Nov 7, 2022 |
| Listing Date | 2022-11-16 |
| Face Value | ₹2 per share |
| Price | ₹319 to ₹336 per share |
| Lot Size | 44 Shares |
| Issue Size | [.] shares of ₹2 (aggregating up to ₹2,205.57 Cr) |
| Fresh Issue | [.] shares of ₹2 (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 50,761,000 shares of ₹2 (aggregating up to ₹1,705.57 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 50% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| Company Promoters | Dr. Naresh Trehan is the company promoter. |
Global Health IPO Tentative Timetable
Global Health IPO opens on Nov 3, 2022, and closes on Nov 7, 2022. The Global Health IPO bid date is from Nov 3, 2022 10.00 A.M. to Nov 7, 2022 5.00 P.M. The Cut-off time for UPI Mandate confirmation is 5 PM on the issue closing day.
| Event | Tentative Date |
| Opening Date | Nov 3, 2022 |
| Closing Date | Nov 7, 2022 |
| Basis of Allotment | Nov 11, 2022 |
| Initiation of Refunds | Nov 14, 2022 |
| Credit of Shares to Demat | Nov 15, 2022 |
| Listing Date | Nov 16, 2022 |
Global Health IPO Lot Size
The Global Health IPO lot size is 44 shares. A retail-individual investor can apply for up to 13 lots (572 shares or ₹192,192).
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 44 | ₹14,784 |
| Retail (Max) | 13 | 572 | ₹192,192 |
| S-HNI (Min) | 14 | 616 | ₹206,976 |
| B-HNI (Min) | 68 | 2,992 | ₹1,005,312 |
Global Health IPO Promoter Holding
| Pre Issue Share Holding | 35% |
| Post Issue Share Holding | 33% |
Company Contact Information
Global Health Limited
Medanta – Mediclinic,
E-18, Defence Colony,
New Delhi, Delhi 110 024,
Phone: +91 124 483 4060
Email: compliance@medanta.org
Website: https://www.medanta.org/
Official Registrar of Global Health IPO
Phone: 04067162222, 04079611000
Email: globalhealth.ipo@kfintech.com
Website: https://karisma.kfintech.com/
One thought on “Medanta Global Health Limited : IPO Price, GMP & Financials 3”